Your session is about to expire
← Back to Search
Empagliflozin for Heart Failure (EMPA HF Trial)
EMPA HF Trial Summary
This trial is testing whether a diabetes medication can help improve heart function in patients with or without diabetes. 60 patients will be given the medication or a placebo for 6 weeks, then the placebo group will be given the medication for 6-12 weeks.
EMPA HF Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowEMPA HF Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.EMPA HF Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am 18 years old or older.I have anemia with hemoglobin below 8g/dL or I am currently bleeding.I have a serious heart valve problem, complex heart condition from birth, or had a heart transplant.I have a history of severe diabetes issues, including emergency treatments in the last 6 months.My doctor plans to adjust my water pill treatment for worsening heart failure.I regularly take high doses of water pills for my condition.I have been taking a water pill daily for at least a month.I have major issues controlling my bladder.I have gained at least 5 lbs recently.My heart failure symptoms are getting worse despite current treatments.My kidney function, measured by eGFR, is at least 20.I speak English.I need to be hospitalized for heart failure now.I am currently on or planning to start dialysis.I have had many urinary tract infections or a severe infection called urosepsis.
- Group 1: Empagliflozin
- Group 2: Placebo, Then Empagliflozin
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any vacancies available in this research project?
"Regrettably, the trial is not currently enrolling patients according to clinicaltrials.gov; this research was initially posted on November 1st 2022 and recently updated on September 21st 2022. However, there are 701 other studies actively recruiting participants at present."
To what extent do the risks of Empagliflozin outweigh its benefits?
"The safety of Empagliflozin was rated at 1, due to it being in the early stages of clinical trials and having limited data regarding its efficacy."
What is the desired outcome of this research endeavor?
"This clinical trial, which will be evaluated on Day 1 and its accompanying time frame, aims to measure the alteration in plasma volume from baseline at 7 days. Secondary objectives include assessing chronic empagliflozin vs placebo effects on change in plasma volume (using I-131 albumin) and total body water (utilizing heavy water [D2O]) during Days 1 & 42 as well as monitoring changes in total body water throughout an open label extension period between Day 1 & 84."
Share this study with friends
Copy Link
Messenger